Johnson & Johnson and Oxford AHSN cement relationship over five-year strategic partnership

Johnson & Johnson and Oxford AHSN cement relationship over five-year strategic partnership

The Oxford AHSN already enjoys a very productive relationship with the global healthcare company Johnson & Johnson (J&J). J&J is one of the largest employers linked to healthcare in our region with its headquarters in High Wycombe.

Find your nearest AHSN

By Johnson & Johnson


 In December 2015, the two organisations entered a strategic partnership, signing a Memorandum of Understanding recognising the synergies between them relating to improving patient care and health outcomes and accelerating access to new innovations and technologies through academic and commercial collaborations. Through this ongoing partnership the Oxford AHSN and J&J are utilising opportunities to share knowledge and expertise to help develop innovative local health services and advance the health of people across the region and beyond.

The Johnson & Johnson family of companies has been a pioneer in the research and development of new products, pharmaceuticals and medical devices that contribute to the health and wellbeing of people around the world. They strive to maintain an environment of innovative product development, conducting all phases of research and development to the highest ethical standard, while advancing pipelines that serve medical needs. The partnership was formed as the Oxford AHSN wanted to gain more global industry input into its programmes while J&J sought greater NHS input and access to smaller companies for partnership opportunities.   

How did the Innovation Exchange help?

The Oxford AHSN and J&J are working together to support the development of new medtech and digital healthcare innovations, develop a vibrant culture of entrepreneurship within the Oxford AHSN region and foster a collaborative ecosystem of partners across life sciences, digital health, and health and social care to accelerate the development and adoption of innovations. The partnership is focused on patient-centric independence and wellbeing solutions enable networking and collaboration between innovators, clinicians, industry and academics. The Oxford AHSN provides access to NHS partners and patient input and fosters commercial partnerships with SMEs. 


Impact & Outcomes

The Buckinghamshire Life Sciences Innovation Centre is a partnership that brings together all the elements needed to support healthcare innovators in developing products. It provides a strong platform for growth and sustainable partnerships between industry, NHS, public health, social care and Buckinghamshire New University. The Oxford AHSN and Johnson & Johnson have both supported this process from its inception. The Commercial Director of Janssen (part of J&J) was appointed as Vice Chair of the Buckinghamshire Life Sciences Partnership Board (Bucks HSC Ventures). 

Get Physical was a partnership to improve health and wellbeing in Berkshire, Buckinghamshire, Milton Keynes and Oxfordshire. It began in 2015 when the Oxford AHSN got together three county sports partnerships, Public Health England, Health Education England Thames Valley and NHS trusts. J&J joined the partnership and assisted in exploring the strategies needed to ensure that NHS staff and patients incorporated regular exercise into their daily lives leading to improved health and an enduring sense of wellbeing. J&J hosted a regional event in November 2016. 

J&J/Janssen was shortlisted for the 2017 Oxford AHSN-OBN Best Public-Private Collaboration Award for ongoing collaborative work with local NHS trusts including work in mental health, inflammatory bowel disease and digital innovation.  

Key health economic and outcomes research projects were presented at the ISPOR Europe conference 2019. Together with J&J/Janssen, the Oxford AHSN presented pathwaypro®, a novel digital technology developed by Accession Healthcare centred around major depressive disorder which aims to give local health economies the right tools to explore the effects before implementing an intervention in a real-world setting. 

Oxford AHSN-IBD was the UK’s first independently funded inflammatory bowel disease network. J&J/Janssen is one of the partners (others include AbbVie and Takeda). The Oxford AHSN coordinated operational management funded by Janssen and acted as an interface between industry and clinical practice which enabled real-time data collection supporting more than 1,600 patients with IBD.  

The partnership has developed over the course of the five years and will continue to do so going forward. Oxford AHSN hopes the partnership will continue to develop with J&J, providing Oxford AHSN with access to big industry.